Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EGFR/HER2-IN-8 (compound 34) is an inhibitor of EGFR/HER2 and DHFR with IC50 values of 0.45, 0.244 and 5.669 μM for EGFR, HER2 and DHFR, respectively. EGFR/HER2-IN-8 can be used in the cancer research that exhibits anticancer activity against several cancer cell lines with high safety profile and selectivity indices [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 1,520.00 | |
50 mg | 10-14 weeks | $ 1,980.00 | |
100 mg | 10-14 weeks | $ 2,500.00 |
Description | EGFR/HER2-IN-8 (compound 34) is an inhibitor of EGFR/HER2 and DHFR with IC50 values of 0.45, 0.244 and 5.669 μM for EGFR, HER2 and DHFR, respectively. EGFR/HER2-IN-8 can be used in the cancer research that exhibits anticancer activity against several cancer cell lines with high safety profile and selectivity indices [1]. |
In vitro | EGFR/HER2-IN-8, at concentrations ranging from 0 to 100 μM over 72 hours, demonstrates significant anticancer efficacy against HepG2, MCF 7, HCT-116, PC-3, and Hela cancer cell lines, while showing preferential cytotoxicity towards these cancer cells over normal WI-38 fetal lung fibroblast cells. The compound's cytotoxic effectiveness was quantified by IC50 values of 7.34 μM for HepG2, 5.19 μM for MCF 7, 9.23 μM for HCT-116, 18.5 μM for PC-3, and 13.02 μM for Hela cell lines, indicating robust anti-cancer activity. Conversely, it exhibited minimal cytotoxicity against the WI-38 cell line, with an IC50 value of 67.25 μM,highlighting its selectivity, particularly towards the MCF-7 breast cancer cell line. |
Molecular Weight | 328.39 |
Formula | C16H16N4O2S |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
EGFR/HER2-IN-8 inhibitor inhibit